| 1 |
Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 2010;25:1487-91.
DOI
ScienceOn
|
| 2 |
Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005;60:605-9.
DOI
ScienceOn
|
| 3 |
Jung HS, Lee JH, Chun EM, Moon JW, Chang JH. Predictors of long-term mortality after hospitalization for acute exacerbation of COPD. Tuberc Respir Dis 2006;60:205-14.
DOI
|
| 4 |
Barbera JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;149:423-9.
DOI
|
| 5 |
Jeong SW, Lee JH, Choi KJ, Hwangbo Y, Kim YY, Lee YJ, et al. Comparisons of clinical characteristics and outcomes in COPD patients hospitalized with community-acquired pneumonia and acute exacerbation. Tuberc Respir Dis 2010;69:31-8.
DOI
|
| 6 |
American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
|
| 7 |
Global Initiative for Chronic Obstructive Lung disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [internet]. [place unknown]: GOLD; c2009. [cited 2009 Nov 18]. Available from: http//www.goldcopd.org.
|
| 8 |
Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
DOI
ScienceOn
|
| 9 |
Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9.
DOI
ScienceOn
|
| 10 |
Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991;114:216-23.
DOI
ScienceOn
|
| 11 |
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
DOI
ScienceOn
|
| 12 |
Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002;19:632-8.
DOI
ScienceOn
|
| 13 |
Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361-8.
DOI
ScienceOn
|
| 14 |
Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
|
| 15 |
Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326-33.
DOI
ScienceOn
|
| 16 |
Jo KW, Ra SW, Chae EJ, Seo JB, Kim NK, Lee JH, et al. Three phenotypes of obstructive lung disease in the elderly. Int J Tuberc Lung Dis 2010;14:1481-8.
|
| 17 |
Viegi G, Matteelli G, Angino A, Scognamiglio A, Baldacci S, Soriano JB, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004;126:1093-101.
DOI
ScienceOn
|
| 18 |
Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci 2011;26:379-85.
DOI
ScienceOn
|
| 19 |
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
DOI
ScienceOn
|
| 20 |
Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
DOI
ScienceOn
|
| 21 |
Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH. Circulating immunoreactive endothelin- 1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993;148:519-22.
DOI
ScienceOn
|
| 22 |
Ryu YJ, Chun EM, Lee JH, Chang JH. Prevalence of depression and anxiety in outpatients with chronic airway lung disease. Korean J Intern Med 2010;25:51-7.
DOI
ScienceOn
|
| 23 |
Crockett AJ, Cranston JM, Moss JR, Alpers JH. The impact of anxiety, depression and living alone in chronic obstructive pulmonary disease. Qual Life Res 2002;11:309-16.
DOI
ScienceOn
|
| 24 |
Dahlen I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002;122:1633-7.
DOI
ScienceOn
|
| 25 |
National Heart, Lung and Blood Institute; National Institutes of Health. Morbidity and mortality: 2007 chart book on cardiovascular, lung and blood diseases [internet]. Bethesda, MD: National Institutes of Health; 2007 [cited 2010 Oct 14]. Available from: http://www.nhlbi.nih.gov/resources/docs/07a-chtbk.pdf.
|
| 26 |
Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
DOI
ScienceOn
|
| 27 |
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
DOI
ScienceOn
|
| 28 |
BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(Suppl 5):S1-28.
|
| 29 |
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:654-8.
DOI
ScienceOn
|
| 30 |
Douglas SL, Daly BJ, Gordon N, Brennan PF. Survival and quality of life: short-term versus long-term ventilator patients. Crit Care Med 2002;30:2655-62.
DOI
ScienceOn
|
| 31 |
Kim MH, Lee K, Kim KU, Park HK, Jeon DS, Kim YS, et al. Risk factors associated with frequent hospital readmissions for exacerbation of COPD. Tuberc Respir Dis 2010;69:243-9.
DOI
|
| 32 |
Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65.
DOI
ScienceOn
|
| 33 |
Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-7.
DOI
ScienceOn
|
| 34 |
Lee S, Lee JS, Song JW, Choi CM, Shim TS, Kim TB, et al. Validation of the Korean version of chronic obstructive pulmonary disease assessment test (CAT) and Dyspnea-12 questionnaire. Tuberc Respir Dis 2010;69:171-6.
DOI
ScienceOn
|
| 35 |
Stoller JK, Ferranti R, Feinstein AR. Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis 1986;134:1129-34.
|
| 36 |
Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010;65:21-6.
DOI
ScienceOn
|
| 37 |
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J 2009;34:648-54.
DOI
ScienceOn
|
| 38 |
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
DOI
ScienceOn
|
webmaster
